Flash Finance

Gland Pharma LimitedGLANDCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹3,043.40
MCap ₹50,206 Cr · P/E 48.9
Gland Pharma Limited — Stock analysis & AI research Gland Pharma Limited — Multibagger AI analysis Gland Pharma Limited — Seasonality — best & worst months Gland Pharma Limited — Technical indicators & charts Gland Pharma Limited — Technical setup — score, trend, support & resistance Gland Pharma Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Mid Cap Stocks List 📈 Stocks Near 52-Week High📈 Strong Trend Stocks (ADX > 25)📈 Bullish EMA Alignment📈 Relative Strength Leaders📈 Volume Dry-Up Stocks📈 Highest Technical Score ⚖️ vs Torrent Pharmaceuticals⚖️ vs Ajanta Pharma 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,743 Cr
Sales · Mar 2026
+22.3% YoY
₹513 Cr
Operating Profit · Mar 2026
+47.6% YoY
29.4%
OPM % · Mar 2026
+20.5% YoY
₹367 Cr
Net Profit · Mar 2026
+96.7% YoY
₹22.26
EPS · Mar 2026
+96.6% YoY

📝 Gland Pharma Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Gland Pharma Limited reported revenue of ₹1,743 crore for the quarter ended March 2026 (Q4 FY26), up 22.3% from ₹1,425 crore in the same quarter last year, and up 2.8% sequentially over the December 2025 quarter.

Net profit rose 96.7% year-on-year to ₹367 crore, from ₹187 crore. Earnings per share (EPS) came in at ₹22.26.

Operating profit stood at ₹513 crore — an operating margin (OPM) of 29.4%, compared with 24.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Gland Pharma Limited posted revenue of ₹6,431 crore, a decline of 64.7% over FY25, with a net profit of ₹1,028 crore (down 48.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹6,431 crore with a net profit of ₹1,028 crore.

Valuation snapshot

At the current price of ₹3,043.40, GLAND has a market capitalisation of ₹50,206 crore and a trailing P/E of about 48.9.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 15th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 45.75%, foreign institutional investors (FIIs) 10.36%, domestic institutional investors (DIIs) 33.21%, public shareholders 10.66%, the government 0.01% of Gland Pharma Limited.

Promoter holding slipped from 51.77% to 45.75% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹50,206 Cr
Current Price ?
₹3,043.4
P/E ?
48.86above ind
Industry P/E ?
35.00
P/B ?
4.85
P/S ?
7.81
P/FCF ?
93.32
Enterprise Value ?
₹50,490 Cr
EV/EBITDA ?
30.98
PEG ?
6.11
Earnings Yield ?
2.4%
Dividend Yield ?
0.59%
Profitability & Returns
Sales (TTM) ?
₹6,431 Cr
OPM ?
25.3%
Profit after tax (TTM) ?
₹1,028 Cr
EPS (TTM) ?
₹62.29
ROCE ?
15.0%
ROE ?
9.9%
ROA ?
8.2%
Growth
Sales — latest qtr ?
₹1,743 Cr
PAT — latest qtr ?
₹367 Cr
YoY qtr sales growth ?
22.3%
YoY qtr profit growth ?
96.7%
Sales growth (3y) ?
21%
Sales growth (5y) ?
13%
Profit growth (3y) ?
8%
Profit growth (5y) ?
1%
Financial Health
Debt ?
₹284 Cr
Debt to Equity ?
0.03
Interest Coverage ?
36.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
45.75%
Change in promoter holding ?
-6.08%
Pledged percentage ?
N/A
Market
Return 3 months ?
24.3%
Return 6 months ?
69.3%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 9387851,2091,3731,5451,53714,0171,4061,3841,4251,5061,4871,6951,743 +22.3% +2.8%
Operating Profit 2901682943243563592,644297360348368314435513 +47.6% +18.0%
Other Income 623938533742514605844588463111 +152.1% +75.7%
Interest 3256510566237118410 +34.2% +154.5%
Depreciation 3838658110593920949696101106108109 +13.8% +1.3%
Profit Before Tax 3111112612902832982,182257299288313284362506 +75.5% +39.7%
Net Profit 232791941941921921,438164205187215184261367 +96.7% +40.4%
EPS 14.084.7811.7911.7811.6511.688.739.9312.4211.3213.0811.1515.8722.26 +96.6% +40.3%
OPM % 30.9% 21.5% 24.3% 23.6% 23.1% 23.3% 18.9% 21.1% 26.0% 24.4% 24.4% 21.1% 25.7% 29.4% +20.5% +14.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹18,232 Cr ₹6,431 Cr ₹6,431 Cr -64.7%
Operating Profit ₹3,649 Cr ₹1,630 Cr ₹1,630 Cr -55.3%
OPM % 20.01% 25.34% 25.34% +26.6%
NPM % 10.93% 15.98% 15.98% +46.2%
Other Income ₹676 Cr ₹316 Cr ₹316 Cr -53.3%
Depreciation ₹1,206 Cr ₹424 Cr ₹424 Cr -64.8%
Interest ₹93 Cr ₹33 Cr ₹33 Cr -64.1%
EBIT ₹2,443 Cr ₹1,206 Cr ₹1,206 Cr -50.7%
PBT ₹3,027 Cr ₹1,465 Cr ₹1,465 Cr -51.6%
Tax ₹1,034 Cr ₹297 Cr ₹297 Cr -71.3%
Net Profit ₹1,992 Cr ₹1,028 Cr ₹1,028 Cr -48.4%
EPS ₹42.40 ₹62.36 ₹62.36 +47.1%
Material Cost ₹6,201 Cr ₹1,650 Cr ₹1,650 Cr -73.4%
Employee Cost ₹4,601 Cr ₹1,217 Cr ₹1,217 Cr -73.5%
Extraordinary Items — ₹24 Cr ₹24 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 16161616 +0.0%
Reserves 7,9428,7079,13410,341 +13.2%
Borrowings 4372314284 -9.6%
Other Liabilities 8141,5151,7081,869 +9.4%
Total Liabilities 8,77810,61111,17312,511 +12.0%
Fixed Assets 1,5713,9474,1474,492 +8.3%
CWIP 177238151342 +126.5%
Investments 0000 —
Other Assets 7,0306,4266,8757,676 +11.7%
Total Assets 8,77810,61111,17312,511 +12.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 3649979151,031 +12.7%
Cash from Investing Activity 1,211-1,7491,718138 -92.0%
Cash from Financing Activity 15-799-433-417 +3.7%
Net Cash Flow 1,590-1,5522,199752 -65.8%
Free Cash Flow 141599521538 +3.3%
CFO/OP 66%98%100%91% -9.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 8810099107 +8.1%
Inventory Days 421278294284 -3.4%
Days Payable 127129143136 -4.9%
Cash Conversion Cycle 382250250255 +2.0%
Working Capital Days 242155173145 -16.2%
ROCE % 15%14%12%15% +25.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 51.83%51.83%51.83%51.83%51.77%45.75% -11.6%
FIIs 7.39%7.90%7.58%7.29%8.74%10.36% +18.5%
DIIs 32.86%32.63%32.99%33.36%30.44%33.21% +9.1%
Public 7.93%7.63%7.62%7.52%9.05%10.66% +17.8%
No. of Shareholders 1,10,67197,15194,57891,5001,08,2661,25,667 +16.1%
Government —————0.01% —

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Gland Pharma Limited's revenue in Q4 FY26?
Gland Pharma Limited reported revenue of ₹1,743 crore for the quarter ended March 2026 (Q4 FY26), up 22.3% from ₹1,425 crore in the same quarter last year, and up 2.8% sequentially over the December 2025 quarter.
What was Gland Pharma Limited's net profit in Q4 FY26?
Net profit rose 96.7% year-on-year to ₹367 crore, from ₹187 crore. Earnings per share (EPS) came in at ₹22.26.
What is GLAND's market capitalisation and P/E ratio?
At the current price of ₹3,043.40, GLAND has a market capitalisation of ₹50,206 crore and a trailing P/E of about 48.9.
Who owns Gland Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 45.75%, foreign institutional investors (FIIs) 10.36%, domestic institutional investors (DIIs) 33.21%, public shareholders 10.66%, the government 0.01% of Gland Pharma Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI